Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX1901 in Moderate to Severe Plaque Psoriasis
NCT06943950Phase 3Not yet recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of SYHX-1901 in plaque psoriasis, sponsored by CSPC Ouyi Pharmaceutical. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
SYHX-1901
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06943950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943950.